Nektar Therapeutics Upgraded to Outperform at Zacks (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday, Stock Ratings Network.com reports. The firm currently has a $12.90 price target on the stock. Zacks‘ price target indicates a potential upside of 10.45% from the company’s current price.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 1.88% on Tuesday, hitting $11.90. 295,251 shares of the company’s stock traded hands. Nektar Therapeutics has a one year low of $7.53 and a one year high of $14.47. The stock’s 50-day moving average is $11.41 and its 200-day moving average is $11.52. The company’s market cap is $1.382 billion.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.08. The company had revenue of $60.91 million for the quarter, compared to the consensus estimate of $54.34 million. The company’s quarterly revenue was up 230.8% on a year-over-year basis. Analysts expect that Nektar Therapeutics will post $-1.16 EPS for the current fiscal year.
Separately, analysts at Piper Jaffray initiated coverage on shares of Nektar Therapeutics in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.32.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.